Dual subcellular compartment delivery of doxorubicin to overcome drug resistant and enhance antitumor activity

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Song, Yan Feng ^a   Liu, Dao Zhou ^a   Cheng, Ying ^a   Liu, Miao ^a   Ye, Wei Liang ^a   Zhang, Bang Le ^a   Liu, Xin You ^a   Zhou, Si Yuan ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC ANTIBIOTIC; CASPASE 3; DOXORUBICIN; DRUG CARRIER; MACROGOL DERIVATIVE; MICELLE; PHOSPHATIDYLETHANOLAMINE; POLYETHYLENE GLYCOL-DISTEAROYLPHOSPHATIDYLETHANOLAMINE;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; CELL SURVIVAL; CHEMISTRY; DRUG EFFECTS; FEMALE; HUMAN; METABOLISM; MICELLE; MITOCHONDRIAL MEMBRANE POTENTIAL; MOUSE; NEOPLASMS; NUDE MOUSE; PATHOLOGY; PH; TISSUE DISTRIBUTION; TUMOR CELL LINE; XENOGRAFT;

ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; APOPTOSIS; CASPASE 3; CELL LINE, TUMOR; CELL SURVIVAL; DOXORUBICIN; DRUG CARRIERS; FEMALE; HUMANS; HYDROGEN-ION CONCENTRATION; MEMBRANE POTENTIAL, MITOCHONDRIAL; MICE; MICE, INBRED BALB C; MICE, NUDE; MICELLES; NEOPLASMS; PHOSPHATIDYLETHANOLAMINES; POLYETHYLENE GLYCOLS; TISSUE DISTRIBUTION; TRANSPLANTATION, HETEROLOGOUS;

EID: 84946213879     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep16125     Document Type: Article

References (63)

1. Kunjachan, S., Rychlik, B., Storm, G., Kiessling, F. & Lammers, T. Multidrug resistance: Physiological principles and nanomedical solutions. Adv Drug Deliv Rev 65, 1852-1865 (2013).
2. Minotti, G., Menna, P., Salvatorelli, E., Cairo, G. & Gianni, L. Anthracyclines: molecular advances and pharmacologic developments in antitumor activity and cardiotoxicity. Pharmacol Rev 56, 185-229 (2004).
3. Singal, P. K. & Iliskovic, N. Doxorubicin-induced cardiomyopathy. N Engl J Med 339, 900-905 (1998).
4. Berthiaume, J. M. & Wallace, K. B. Adriamycin-induced oxidative mitochondrial cardiotoxicity. Cell Biol Toxicol 23, 15-25 (2007).
5. Schinkel, A. H. & Jonker, J. W. Mammalian drug efflux transporters of the ATP binding cassette (ABC) family: an overview. Adv Drug Deliv Rev 55, 3-29 (2003).
6. Maraldi, N. M. et al. P-glycoprotein subcellular localization and cell morphotype in MDR1 gene-transfected human osteosarcoma cells. Biol Cell 91, 17-28 (1999).
7. Rajagopal, A. & Simon, S. M. Subcellular localization and activity of multidrug resistance proteins. Mol Biol Cell 14, 3389-3399 (2003).
8. Toninello, A. Editorial: Mitochondria and subcellular organelles as treatment targets against pathological conditions. Curr Pharm Des 20, 153-154 (2014).
9. Galluzzi, L., Larochette, N., Zamzami, N. & Kroemer, G. Mitochondria as therapeutic targets for cancer chemotherapy. Oncogene 25, 4812-4830 (2006).
10. Hockenbery, D. M. Targeting mitochondria for cancer therapy. Environ Mol Mutagen 51, 476-489 (2010).
11. Fantin, V. R. & Leder, P. Mitochondriotoxic compounds for cancer therapy. Oncogene 25, 4787-4797 (2006).
12. Sakhrani, N. M. & Padh, H. Organelle targeting: third level of drug targeting. Drug Des Devel Ther 7, 585-599 (2013).
13. Mallick, A. et al. Dual drug conjugated nanoparticle for simultaneous targeting of mitochondria and nucleus in cancer cells. ACS Appl Mater Interfaces 7, 7584-7598 (2015).
14. Zhou, J. et al. The anticancer efficacy of paclitaxel liposomes modified with mitochondrial targeting conjugate in resistant lung cancer. Biomaterials 34, 3626-3638 (2013).
15. Han, M. et al. Molecular mechanism study of chemosensitization of doxorubicin-resistant human myelogenous leukemia cells induced by a composite polymer micelle. Int J Pharm 420, 404-411 (2011).
16. Modica-Napolitano, J. S. & Aprille, J. R. Delocalized lipophilic cations selectively target the mitochondria of carcinoma cells. Adv Drug Deliv Rev 49, 63-70 (2001).
17. Manetta, A. et al. Failure to enhance the in vivo killing of human ovarian carcinoma by sequential treatment with dequalinium chloride and tumor necrosis factor. Gynecol Oncol 50, 38-44 (1993).
18. D'Souza, G. G., Rammohan, R., Cheng, S. M., Torchilin, V. P. & Weissig, V. DQAsome-mediated delivery of plasmid DNA toward mitochondria in living cells. J Control Release 92, 189-197 (2003).
19. Weissig, V., D'Souza, G. G. & Torchilin, V. P. DQAsome/DNA complexes release DNA upon contact with isolated mouse liver mitochondria. J Control Release 75, 401-408 (2001).
20. Weissig, V. et al. DQAsomes: a novel potential drug and gene delivery system made from Dequalinium. Pharm Res 15, 334-337 (1998).
21. Song Y. F. et al. Preparation and anti-tumor activity of mitochondrial targeting DQA-DOX conjugate. Northwest Pharm J 7, 283-286 (2015).
22. Vilner, B. J., John, C. S. & Bowen, W. D. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res 55, 408-413 (1995).
23. Mir, S. U., Ahmed, I. S., Arnold, S. & Craven, R. J. Elevated progesterone receptor membrane component 1/sigma-2 receptor levels in lung tumors and plasma from lung cancer patients. Int J Cancer 131, E1-E9 (2012).
24. Aydar, E., Onganer, P., Perrett, R., Djamgoz, M. B. & Palmer, C. P. The expression and functional characterization of sigma (sigma) 1 receptors in breast cancer cell lines. Cancer Lett 242, 245-257 (2006).
25. Megalizzi, V., Le Mercier, M. & Decaestecker, C. Sigma receptors and their ligands in cancer biology: overview and new perspectives for cancer therapy. Med Res Rev 32, 410-427 (2012).
26. Hashim, Y. M. et al. Targeted pancreatic cancer therapy with the small molecule drug conjugate SW IV-134. Mol Oncol 8, 956-967 (2014).
27. Banerjee, R., Tyagi, P., Li, S. & Huang, L. Anisamide-targeted stealth liposomes: a potent carrier for targeting doxorubicin to human prostate cancer cells. Int J Cancer 112, 693-700 (2004).
28. Li, S. D. & Huang, L. Targeted delivery of antisense oligodeoxynucleotide and small interference RNA into lung cancer cells. Mol Pharm 3, 579-588 (2006).
29. Garg, N. K., Dwivedi, P., Campbell, C. & Tyagi, R. K. Site specific/targeted delivery of gemcitabine through anisamide anchored chitosan/poly ethylene glycol nanoparticles: an improved understanding of lung cancer therapeutic intervention. Eur J Pharm Sci 47, 1006-1014 (2012).
30. Yang, Y. et al. Nanoparticle delivery of pooled siRNA for effective treatment of non-small cell lung cancer. Mol Pharm 9, 2280-2289 (2012).
31. Lu, L. et al. Anisamide-Decorated pH-Sensitive Degradable Chimaeric Polymersomes Mediate Potent and Targeted Protein Delivery to Lung Cancer Cells. Biomacromolecules 16, 1726-1735 (2015).
32. Stein, U., Walther, W., Lemm, M., Naundorf, H. & Fichtner, I. Development and characterisation of novel human multidrug resistant mammary carcinoma lines in vitro and in vivo. Int J Cancer 72, 885-891 (1997).
33. Li, Y. C. et al. Mitochondrial targeting drug lonidamine triggered apoptosis in doxorubicin-resistant HepG2 cells. Life Sci 71, 2729-2740 (2002).
34. Du J. B. et al. PEG-detachable lipid-polymer hybrid nanoparticle for delivery of chemotherapy drugs to cancer cells. Anticancer Drugs 25, 751-766 (2014).
35. Qiu, L. Y. & Bae, Y. H. Self-assembled polyethylenimine-graft-poly(epsilon-caprolactone) micelles as potential dual carriers of genes and anticancer drugs. Biomaterials 28, 4132-4142 (2007).
36. Sawant, R. R. & Torchilin, V. P. Enhanced cytotoxicity of TATp-bearing paclitaxel-loaded micelles in vitro and in vivo. Int J Pharm 374, 114-118 (2009).
37. Hann, S. S. et al. Repression of phosphoinositide-dependent protein kinase 1 expression by ciglitazone via Egr-1 represents a new approach for inhibition of lung cancer cell growth. Mol Cancer 13, 149 (2014).
38. Qiu, L. et al. Enhanced effect of pH-sensitive mixed copolymer micelles for overcoming multidrug resistance of doxorubicin. Biomaterials 35, 9877-9887 (2014).
39. Ye, W. L. et al. Cellular uptake and antitumor activity of DOX-hyd-PEG-FA nanoparticles. PLoS One 9, e97358 (2014).
40. Lv, S. et al. Doxorubicin-loaded amphiphilic polypeptide-based nanoparticles as an efficient drug delivery system for cancer therapy. Acta Biomater 9, 9330-9342 (2013).
41. Wu, H., Zhu, L. & Torchilin, V. P. pH-sensitive poly(histidine)-PEG/DSPE-PEG co-polymer micelles for cytosolic drug delivery. Biomaterials 34, 1213-1222 (2013).
42. Li, S. et al. Doxorubicin loaded pH-responsive micelles capable of rapid intracellular drug release for potential tumor therapy. J Biomed Nanotechnol 10, 1480-1489 (2014).
43. Kastantin, M. et al. Thermodynamic and kinetic stability of DSPE-PEG(2000) micelles in the presence of bovine serum albumin. J Phys Chem B 114, 12632-12640 (2010).
44. Wu, H., Yao, L., Mei, J. & Li, F. Development of synthetic of peptide-functionalized liposome for enhanced targeted ovarian carcinoma therapy. Int J Clin Exp Pathol 8, 207-216 (2015).
45. Han, H. S. et al. Bioreducible core-crosslinked hyaluronic acid micelle for targeted cancer therapy. J Control Release 200, 158-166 (2015).
46. Zong, T. et al. Synergistic dual-ligand doxorubicin liposomes improve targeting and therapeutic efficacy of brain glioma in animals. Mol Pharm 11, 2346-2357 (2014).
47. Dobrovolskaia, M. A., Aggarwal, P., Hall, J. B. & McNeil, S. E. Preclinical studies to understand nanoparticle interaction with the immune system and its potential effects on nanoparticle biodistribution. Mol Pharm 5, 487-495 (2008).
48. Duan, X. & Li, Y. Physicochemical characteristics of nanoparticles affect circulation, biodistribution, cellular internalization, and trafficking. Small 9, 1521-1532 (2013).
49. Xiao, K. et al. The effect of surface charge on in vivo biodistribution of PEG-oligocholic acid based micellar nanoparticles. Biomaterials 32, 3435-3446 (2011).
50. Zhang, Z. et al. Intracellular pH-sensitive PEG-block-acetalated-dextrans as efficient drug delivery platforms. ACS Appl Mater Interfaces 5, 10760-10766 (2013).
51. Liu, J. et al. pH-sensitive nano-systems for drug delivery in cancer therapy. Biotechnol Adv 32, 693-710 (2014).
52. Ferreira, D. S., Lopes, S. C., Franco, M. S. & Oliveira, M. C. pH-sensitive liposomes for drug delivery in cancer treatment. Ther Deliv 4, 1099-1123 (2013).
53. Suksiriworapong, J., Rungvimolsin, T., A-gomol, A., Junyaprasert, V. B. & Chantasart, D. Development and characterization of lyophilized diazepam-loaded polymeric micelles. AAPS PharmSciTech 15, 52-64 (2014).
54. Zhou, Z., Li, L., Yang, Y., Xu, X. & Huang, Y. Tumor targeting by pH-sensitive, biodegradable, cross-linked N-(2-hydroxypropyl) methacrylamide copolymer micelles. Biomaterials 35, 6622-6635 (2014).
55. Han, J., Lee, T. H., Tung, C. H. & Lee, D. Y. Design and synthesis of a mitochondria-targeting carrier for small molecule drugs. Org Biomol Chem 12, 9793-9796 (2014).
56. Mizusako, H., Tagami, T., Hattori, K. & Ozeki, T. Active Drug Targeting of a Folate-Based Cyclodextrin-Doxorubicin Conjugate and the Cytotoxic Effect on Drug-Resistant Mammary Tumor Cells In Vitro. J Pharm Sci (2015).
57. Han, M. et al. Mitochondrial delivery of doxorubicin via triphenylphosphine modification for overcoming drug resistance in MDA-MB-435/DOX cells. Mol Pharm 11, 2640-2649 (2014).
58. Wang, S. et al. Doxorubicin induces apoptosis in normal and tumor cells via distinctly different mechanisms. intermediacy of H(2)O(2)- and p53-dependent pathways. J Biol Chem 279, 25535-25543 (2004).
59. Mizutani, H., Tada-Oikawa, S., Hiraku, Y., Kojima, M. & Kawanishi, S. Mechanism of apoptosis induced by doxorubicin through the generation of hydrogen peroxide. Life Sci 76, 1439-1453 (2005).
60. Yamada, Y. & Harashima, H. Mitochondrial drug delivery systems for macromolecule and their therapeutic application to mitochondrial diseases. Adv Drug Deliv Rev 60, 1439-1462 (2008).
61. Jezek, P. & Plecita-Hlavata, L. Mitochondrial reticulum network dynamics in relation to oxidative stress, redox regulation, and hypoxia. Int J Biochem Cell Biol 41, 1790-1804 (2009).
62. Goldman, R., Facchinetti, T., Bach, D., Raz, A. & Shinitzky, M. A differential interaction of daunomycin, adriamycin and their derivatives with human erythrocytes and phospholipid bilayers. Biochim Biophys Acta 512, 254-269 (1978).
63. Jung, K. & Reszka, R. Mitochondria as subcellular targets for clinically useful anthracyclines. Adv Drug Deliv Rev 49, 87-105 (2001).